Alpha 2.0
Login Register
» Authors » Y Nannya

Y Nannya

Explore the profile of Y Nannya including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 167
Followers 0
Related Specialties
General Surgery
Hematology
Oncology
Top 10 Co-Authors
M Kurokawa
T Takahashi
Y Kanda
K Kumano
S Chiba
T Hamaki
K Oshima
K Kataoka
A Miwa
N Takezako
Published In
Bone Marrow Transplant
J Chemother
Leukemia
Clin Lab Haematol
Br J Dermatol
Affiliations
Soon will be listed here.
Recent Articles
1.
A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia
Sakai H, Hosono N, Nakazawa H, Przychodzen B, Polprasert C, Carraway H, et al.
Leukemia . 2017 Nov; 32(3):839-843. PMID: 29099495
No abstract available.
2.
Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan
Yoshimi A, Toya T, Nannya Y, Takaoka K, Kirito K, Ito E, et al.
Ann Oncol . 2016 Feb; 27(5):887-95. PMID: 26884589
Background: Inherited thrombocytopenia (IT) contains several forms of familial thrombocytopenia and some of them have propensity to hematological malignancies. The etiological and genetic features of this heterogeneous syndrome have not...
3.
Acute pericarditis before engraftment in hematopoietic stem cell transplantation
Shinohara A, Honda A, Nukina A, Takaoka K, Tsukamoto A, Hangai S, et al.
Bone Marrow Transplant . 2015 Nov; 51(3):459-61. PMID: 26595074
No abstract available.
4.
A randomized controlled study evaluating the efficacy of aprepitant for highly/moderately emetogenic chemotherapies in hematological malignancies
Nasu R, Nannya Y, Kurokawa M
Int J Hematol . 2015 Feb; 101(4):376-85. PMID: 25644148
Chemotherapy-induced nausea and vomiting (CINV) is a serious complication of treatments of hematological malignancies. Although aprepitant, an NK1 receptor antagonist, has been shown to control CINV in highly emetogenic therapies...
5.
HapMap SNP Scanner: an online program to mine SNPs responsible for cell phenotype
Yamamura T, Hikita J, Bleakley M, Hirosawa T, Sato-Otsubo A, Torikai H, et al.
Tissue Antigens . 2012 May; 80(2):119-25. PMID: 22568758
Minor histocompatibility (H) antigens are targets of graft-vs-host disease and graft-vs-tumor responses after human leukocyte antigen matched allogeneic hematopoietic stem cell transplantation. Recently, we reported a strategy for genetic mapping...
6.
The clinical role of procalcitonin in hematopoietic SCT
Koya J, Nannya Y, Ichikawa M, Kurokawa M
Bone Marrow Transplant . 2012 Feb; 47(10):1326-31. PMID: 22343672
Infectious disease following hematopoietic SCT (HSCT) is a major cause of TRM. The more valuable markers to distinguish infections disease from non-infectious complications are needed. Procalcitonin (PCT) and C-reactive protein...
7.
Post-transplant endothelial disorder after hematopoietic SCT: a blinded autopsy study
Goyama S, Takeuchi K, Kanda Y, Nannya Y, Chiba S, Fukayama M, et al.
Bone Marrow Transplant . 2011 Dec; 47(9):1243-5. PMID: 22179557
No abstract available.
8.
Voriconazole is effective as secondary antifungal prophylaxis in leukemia patients with prior pulmonary fungal disease: case series and review of literature
Masamoto Y, Nannya Y, Kurokawa M
J Chemother . 2011 Apr; 23(1):17-23. PMID: 21482489
Although previous invasive fungal diseases (IFD) pose a significant risk of reactivation during successive chemotherapies in patients with acute leukemia, and secondary antifungal prophylaxis is regarded as mandatory, much remains...
9.
Disseminated tuberculosis following unrelated cord blood transplantation for refractory peripheral T-cell lymphoma: Clinical role of serum procalcitonin levels
Koya J, Nannya Y, Yoshizato T, Ono K, Seo S, Nakagawa M, et al.
J Infect . 2011 Feb; 62(3):237-40. PMID: 21281675
No abstract available.
10.
Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma
Ueda K, Nannya Y, Asai T, Yamamoto G, Hangaishi A, Takahashi T, et al.
J Chemother . 2010 Mar; 22(1):54-7. PMID: 20227994
Combined therapy of rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin (R-ESHAP) has been one of the most frequently used salvage regimens for relapsed/refractory non-Hodgkin's lymphoma. In 2002, we introduced the...